Key Insights• According to the research report, "UK Antacids Market Outlook, 2031," published by Actual Market Research, the UK Antacids Market is anticipated to add to more than 92.40 Million by 2026-31.• Gastro-oesophageal reflux disease (GORD) represents one of the most common chronic digestive complaints across the United Kingdom, affecting roughly 20% to 25% of the UK adult population (nearly 1 in 4 adults). High obesity rates, stressful lifestyle factors, and an aging demographic drive consistent baseline demand for immediate over-the-counter (OTC) antacids. Furthermore, high system pressure on primary healthcare services and long NHS wait times for GP consultations encourage consumers to rely heavily on community pharmacies and OTC self-medication for rapid relief. Digital activity mirrors this trend, with UK-based search queries for acid reflux averaging over 60,000 monthly searches and showing sharp spikes during festive periods like Christmas.• The UK market is structurally distinct due to the overwhelming market dominance of alginate-based raft-forming antacids, pioneered by UK-headquartered Reckitt's Gaviscon brand. While standard antacids rely solely on neutralizing gastric pH through basic minerals (such as calcium carbonate or magnesium hydroxide), alginate formulations react with gastric juice to build a viscous, raft-like foam barrier that floats directly on top of the stomach contents. This mechanical action physically halts acid, pepsin, and bile from refluxing back up into the sensitive oesophageal lining for up to 4 hours, establishing alginate technology as the standard of care for immediate, non-prescription reflux control across British healthcare networks.• Dosage preferences in the UK showcase high demand for both chewable solid tablets and liquid suspensions.

Liquid dosage forms hold a particularly dominant share in hospital and community care settings due to their rapid onset of action and ease of administration for elderly or dysphagic patientsMarket Outlook• High-street community pharmacies (such as Boots and Superdrug) and major supermarket chains continue to generate the largest share of physical point-of-sale volume. However, online retail channels and NHS-integrated digital pharmacy platforms are experiencing rapid adoption. Direct-to-consumer digital storefronts allow consumers to set up automated repeat-subscription orders for bulk-pack antacids, while digital health apps focusing on gut monitoring are transforming brand engagement and building long-term brand loyalty.• Product development pipelines across the UK are heavily focused on multi-action formulations that combine traditional acid-neutralizing minerals with anti-foaming agents like simethicone to treat trapped wind and heartburn simultaneously. Furthermore, consumer demand is rapidly shifting toward clean-label formulations specifically sugar-free, artificial dye-free, and natural plant-infused lines (incorporating botanicals like peppermint, ginger, or chamomile) to cater to health-conscious and diabetic populations.• Market leadership in the UK is dominated by multinational consumer health leaders including Reckitt Benckiser Group PLC (Gaviscon), Haleon (Tums), Bayer AG, Sanofi, and Procter & Gamble, operating under strict oversight and industry representation provided by the Medicines and Healthcare products Regulatory Agency (MHRA), the Proprietary Association of Great Britain (PAGB), and patient advocacy groups like Guts UK Charity.Market DynamicsDriver: Self-care culture & primary care access pressuresHigh strain on the UK National Health Service (NHS) and longer wait times for non-emergency GP appointments have significantly accelerated a reliance on self-care. Encouraged by community pharmacists and public health messaging, UK consumers increasingly turn to over-the-counter (OTC) antacids as their first line of defense for immediate heartburn and indigestion relief.Challenge: Prolonged usage risks & MHRA labeling complianceExcessive or continuous reliance on mineral-based antacids presents significant health risks, including hypercalcaemia, rebound acidity, and potential masking of underlying peptic ulcers or stomach cancers. Sourcing and compliance teams must navigate strict guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding side-effect disclosures, maximum daily dosages, and mandatory advice directing consumers to consult a GP if symptoms persist beyond 7 to 14 days.Trend: Rise of alginate raft-formers & gummy formatsConsumer preference in the UK is steadily expanding beyond basic chalky tablets (such as traditional calcium/magnesium carbonate combinations) toward alginate raft-forming formulations (e.g., Gaviscon variants) that physically block acid reflux.

Additionally, manufacturers are expanding into chewables, soft-chews, and gummy delivery systems to appeal to younger, waterless-on-the-go consumers.Procurement and Industry Impact • Calcium carbonate remains the baseline active pharmaceutical ingredient (API) in UK antacid manufacturing, capturing 35.5% of global active ingredient demand. Procurement teams rely on medical-grade mineral suppliers subject to strict European Pharmacopoeia (Ph. Eur.) purity standards and global chemical logistics costs.• The massive domestic and export demand for alginate-based formulations has triggered major industrial scaling. Illustrating this industrial pivot, Reckitt Benckiser committed $160 million (£125+ million) to expand its primary Gaviscon alginate production facility in Hull, UK, reflecting high supply chain investment in liquid-compounding equipment and specialized alginate raw material harvesting.• High-street community pharmacies (e.g., Boots, Superdrug) and major supermarket chains control over 53% of OTC distribution. To maintain high-volume retail listings and front-of-pharmacy shelf presence, antacid brand procurement and commercial teams allocate substantial trade promotion spend and shelf-placement fees across national retail accounts.Segment AnalysisUK Antacids Market By Drug Class• Acid neutralizers remain an important first-line self-care option in the UK because they directly neutralize stomach acid and can provide rapid relief for occasional heartburn and indigestion. Common ingredients include calcium carbonate, magnesium compounds, aluminium hydroxide and sodium bicarbonate.

NHS guidance notes that antacids can relieve symptoms for a few hours and are available from pharmacies and shops without a prescription. Alginates are also frequently incorporated into UK products to create a protective barrier against reflux.• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-suppression position than conventional antacids. Medicines such as omeprazole, lansoprazole and pantoprazole reduce gastric acid production and are used for recurrent indigestion, reflux and acid-related disease. UK consumers can access some PPI products without a prescription, while stronger or longer-duration treatment may be prescribed. NHS guidance indicates that PPIs are generally more effective than H2 blockers at reducing stomach acid, making them important when symptoms are persistent rather than occasional.• H2 antagonists reduce gastric acid secretion through histamine H2-receptor blockade and provide an alternative to PPIs. The UK market includes products such as famotidine, cimetidine and nizatidine, with NHS guidance noting that these can be purchased from pharmacies without a prescription for short-term treatment.

Their positioning is particularly relevant for consumers seeking acid suppression when a PPI is unsuitable or not preferred.• Pro-motility agents represent a specialized segment because they address gastrointestinal movement rather than simply neutralizing or suppressing acid. Their relevance is greater when reflux or upper-GI symptoms are associated with delayed gastric emptying or motility abnormalities. Consequently, this category is more clinically directed and less closely connected with routine UK consumer self-medication than conventional antacids.• Combination formulations are particularly significant in the UK because products can address several mechanisms simultaneously. NHS guidance identifies formulations combining antacid ingredients with alginates and/or simeticone; alginates provide a protective barrier against reflux while simeticone can help reduce flatulence. This makes combination products attractive for consumers experiencing heartburn together with reflux or gas-related discomfort.UK Antacids Market By Dosage Form• Tablets and chewables are highly suited to portable, on-demand treatment and are convenient for consumers experiencing symptoms after meals, during travel or away from home. Chewable formats eliminate the need for water and allow relatively simple unit-based dosing.

NHS guidance confirms that antacids are available in chewable-tablet form and can be purchased from pharmacies and shops without a prescription.• Liquid suspensions provide an alternative for consumers who prefer liquids or have difficulty swallowing tablets. They can accommodate combinations of aluminium, magnesium and other active ingredients and can be positioned for rapid symptomatic relief. Accurate measuring, product consistency and flavour are particularly important because consumers directly perceive the texture and taste of liquid gastrointestinal medicines.• Powders provide flexibility for consumers seeking non-tablet administration and can be formulated for rapid dispersion after preparation. Their portability can be useful, although the need to mix or prepare the product introduces an additional step compared with chewables and ready-to-use liquids. Moisture-resistant packaging and clear dosage instructions therefore become important product-development considerations.• Gels and syrups provide smooth administration and can be particularly attractive to consumers who dislike swallowing tablets. Gel-like formulations are also well suited to reflux-barrier concepts because alginate-containing products can create a physical barrier that reduces the movement of stomach contents into the oesophagus.

NHS guidance specifically describes alginate-containing antacids as products that can line the food pipe and reduce reflux.• Gummies and other formats represent a newer consumer-focused direction for gastrointestinal self-care. Gummies can improve portability and make administration more familiar to consumers accustomed to confectionery-style supplements. However, incorporating sufficient quantities of traditional antacid ingredients while maintaining acceptable taste, texture and stability can be technically challenging. Other formats, including rapidly dispersible and effervescent products, can differentiate themselves through convenience.UK Antacids Market By Indication• Gastroesophageal Reflux Disease (GORD) is an important indication for the UK's broader acid-control category. A UK population study involving 4,432 adults found gastro-oesophageal reflux symptoms in 28.7% of respondents, although fewer than 25% of people reporting these symptoms had consulted a healthcare professional during the preceding year. This highlights the importance of self-care products and pharmacy-based treatment in the UK reflux environment.• Heartburn is a major driver of consumer self-medication because it is a recognizable symptom that can often be managed initially through lifestyle measures and pharmacy medicines.

NHS guidance recommends antacids or alginates for short-term symptom relief and advises medical evaluation when heartburn occurs frequently or when associated warning symptoms are present. This supports a stepped-treatment structure ranging from rapid-relief antacids to longer-term acid suppression.• Peptic ulcer represents a more clinically managed indication than routine heartburn. Antacids can provide symptomatic relief from acid-related discomfort, but they do not address the underlying cause of an ulcer. Consequently, PPIs and other disease-directed treatments have a more important role when an ulcer has been diagnosed. The NHS includes stomach ulcer among conditions for which antacids may help symptoms, while emphasizing that antacids do not treat the underlying cause.• Others include indigestion, acid regurgitation, gastritis-related discomfort and other upper-GI symptoms. NHS guidance identifies indigestion as an important setting for antacid, alginate and PPI use, creating a broader consumer market beyond diagnosed GORD.

This segment is particularly relevant to self-care because consumers may purchase treatment based on symptoms without having received a formal gastrointestinal diagnosis.UK Antacids Market By Distribution Channel• Retail pharmacies remain strategically important because UK consumers can obtain many gastrointestinal medicines directly from pharmacies, where pharmacist advice can help determine an appropriate treatment. The UK's medicine classification system distinguishes between General Sales List medicines, Pharmacy medicines and Prescription Only Medicines, creating different levels of consumer access depending on the product.• Hospital pharmacies primarily serve patients receiving clinically supervised treatment for diagnosed GORD, peptic ulcers, gastrointestinal disorders and other complex conditions. Their demand is therefore more closely linked to physician prescribing, hospital formularies and medication-management requirements than to spontaneous OTC purchases. Hospital pharmacy also becomes particularly relevant when gastrointestinal treatment needs to be coordinated with other medicines.• Online pharmacies / E-commerce provide consumers with convenience, home delivery, product comparison and repeat purchasing. The UK has a formal regulatory system for online medicine sellers: the MHRA maintains a register of websites authorized to sell medicines online. This is particularly important because the MHRA warns consumers about unauthorized online medicine sellers and the potential risk of falsified or unlicensed medicines.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Antacids Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Drug Class• Acid Neutralizers• Proton Pump Inhibitors (PPIs)• H2 Antagonists• Pro-Motility Agents• Combination FormulationsBy Dosage Form• Tablets & Chewables• Liquid Suspensions• Powders• Gels & Syrups• Gummies & OtherBy Indication• Gastroesophageal Reflux Disease• Heartburn• Peptic Ulcer• OthersBy Distribution Channel• Retail Pharmacies• Hospital Pharmacies• Online Pharmacies / E-Commerce.